Answers are grounded in this paper and cite their sources.
In patients with metastatic pancreatic adenocarcinoma, nab-paclitaxel plus gemcitabine significantly improved overall survival, progression-free survival, and response rate, but rates of peripheral neuropathy and myelosuppression were increased. (Funded by Celgene; ClinicalTrials.gov number, NCT00844649.).
No takes yet. Share an insight, caveat, or question.
Hoff et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: